Prevention of urotoxic effects of oxazaphosphorines such as cyclophosphamide, ifosfamide.
Antineoplastic as IV bolus: Adult: 20% of the antineoplastic dose on a weight for weight basis given IV at 4-hourly intervals, beginning at the same time as the antineoplastic inj at 0 hr, 4 and 8 hr. Children: Carry out administrations more frequently and at shorter intervals. Antineoplastic as continuous infusion: 20% of the total antineoplastic dose given by IV inj, followed by 100% of the total antineoplastic dose by IV infusion over 24 hr, and then followed by up to 50% by infusion over a further 12 hr.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Mesna disulfide, which is physically inert, is reduced in the renal tubular epithelium to mesna, which binds to and detoxifies urotoxic metabolites of oxazophosphorines
Protective effect applies only to the urinary tract.
Risk-benefit should be considered when the following medical problems exist - Sensitivity to mesna and other thiol compounds; patient monitoring.
GI effects, headache, malaise, skin rash, other allergic symptoms, vein irritation